KOSDAQBiotech & Pharma246960

SCL Science

₩2,035▲ 7.56%2026-11-18 close
Market Cap
₩70.8B
Turnover
₩300M
Volume
130K
Shares out.
34.8M
PER
—
PBR
2.8×
EPS
-₩118
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Up Three Straight Years; Losses Persist

SCL Science's revenue rose for three consecutive years to KRW 22 billion in 2025, but operating losses have continued through 2022 to 2025, and the third quarter of 2026 returned to an operating loss.

  1. 1

    Revenue grew from KRW 370 million in 2022 to KRW 22 billion in 2025, up 364.6% year on year in 2025.

  2. 2

    Operating losses narrowed each year from 2022 to 2025, but the company stayed in the red for four consecutive years, with a 2025 operating margin of -15.4%.

  3. 3

    After an operating profit of KRW 406 million in Q2 2026, the company posted an operating loss of KRW 190 million in Q3 2026.

  4. 4

    The debt-to-equity ratio rose to 240.1% at end-2025 from 55.0% in 2024, with total liabilities of KRW 56.4 billion.

  5. 5

    The business spans biologics logistics, genetic testing, a hemostatic product and R&D, each with a different profit and cost profile.

02

Business structure

SCL Science builds three business lines on its protein-based platform technology: medical sealants, biologics logistics and medical diagnostics. The logistics unit runs an IoT-based cold chain that follows domestic and international regulatory standards and moves human-derived materials and drugs.

In 2025 it added regional business rights from a Seoul-based research institute to widen its nationwide network. The company said roughly half of the first-half 2026 increase in standalone revenue came from its Yeongnam and Honam cold chain logistics business.

The hemostatic product InnoSEAL Plus DL is supported by a multicenter clinical study published in the journal Biomedicines. The company said supply-contract revenue from this product would be reflected in the second half of 2026.

Its subsidiary SCL Healthcare joined the group in March 2025, and in the first half of 2026 it recorded revenue of KRW 5.05 billion and an operating profit of KRW 57 million after turning profitable.

SCL Healthcare's core activities are CRO-based central lab services (C-LAB) and genetic-analysis precision medicine tests, with cancer gene, adult disease and gut metabolite (TMAO) test volumes rising. The company has said it is pursuing a merger with this subsidiary.

Its AI-focused cancer vaccine subsidiary has secured a patent for predicting response to immuno-oncology therapy and is expanding its R&D pipeline. Because logistics and testing earnings sit alongside an R&D pipeline under one roof, profit structures differ markedly across the units.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7B₩200M2.4%
2025Q4₩8.3B-₩800M−10.2%
2026Q1₩7.7B-₩600M−8.5%
2026Q2₩7.6B₩400M5.3%
2026Q3₩7.9B-₩200M−2.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩400M-₩4.6B-₩6B−1245.4%−45.8%134.0%
2023₩1.3B-₩4B-₩5B−303.8%−26.6%59.5%
2024₩4.7B-₩3.7B-₩3.7B−77.3%−24.0%55.0%
2025₩22B-₩3.4B-₩3.9B−15.4%−16.1%240.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

In the annual DART-filed results, revenue rose from KRW 370 million in 2022 to KRW 1.32 billion in 2023 (up 257.5% year on year), KRW 4.74 billion in 2024 (up 258.3%), and KRW 22 billion in 2025 (up 364.6%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating losses shrank each year, from KRW 4.61 billion in 2022 to KRW 4.02 billion in 2023, KRW 3.66 billion in 2024 and KRW 3.4 billion in 2025, and the company recorded losses for four consecutive years from 2022 to 2025. The operating margin improved from -1,245.4% in 2022 to -15.4% in 2025.

Net loss attributable to controlling shareholders widened to KRW 3.93 billion in 2025 from KRW 3.73 billion in 2024, and the net loss including non-controlling interests was KRW 4.12 billion in 2025.

At end-2025, total liabilities were KRW 56.4 billion and total equity was KRW 23.5 billion, so the debt-to-equity ratio reached 240.1%, up from 55.0% in 2024. Operating cash flow was negative every year: -KRW 4.1 billion in 2022, -KRW 2.82 billion in 2023, -KRW 5.96 billion in 2024 and -KRW 2.17 billion in 2025.

Quarterly, operating profit of KRW 169 million in Q3 2025 turned into an operating loss of KRW 848 million in Q4 2025, followed by a KRW 648 million operating loss in Q1 2026, an operating profit of KRW 406 million in Q2 2026, and an operating loss of KRW 190 million in Q3 2026.

Q3 2026 revenue was KRW 7.85 billion, up 3.4% from the prior quarter and 12.8% from a year earlier. The company's disclosed cumulative consolidated revenue for the first three quarters of 2026 was KRW 23.1 billion, up 68% year on year.

The company attributed the consolidated operating loss to higher R&D and investment costs at its cancer vaccine subsidiary and said the core business's profitability had not declined.

In Q1 2026, the net loss attributable to controlling shareholders of KRW 850 million exceeded the operating loss of KRW 648 million, so non-operating items had a larger effect. The company said first-half net income included convertible bond valuation gains and losses and interest expense, which are non-cash items.

05

Industry analysis

SCL Science sits within the biopharma sector but puts its weight on service areas such as logistics and testing rather than new drug development or large-scale contract manufacturing.

Compared with peers such as Samsung Biologics and Celltrion, which build their businesses around large production capacity and product pipelines, its business model and scale differ sharply.

As development and commercialization of biologic drugs grow, demand for safely transporting and testing biologics can rise alongside, which forms the backdrop for its logistics business.

Still, annual revenue was about KRW 22 billion in 2025, and quarterly revenue fell 7.6% in Q1 2026 and 0.9% in Q2 before rising 3.4% in Q3, a pattern that suggests logistics and testing demand may move with client schedules and contract timing.

Cold chain transport requires temperature control and regulatory compliance capabilities, and the company positions itself on specialized transport that meets domestic and international rules.

In medical diagnostics, growth depends on expanding genetic test menus and test volumes, and competitive intensity varies by player, so company-by-company comparison is needed.

The hemostatic product InnoSEAL Plus DL is presented as a new revenue source, but how large its sales become will only be visible once the second-half 2026 supply-contract revenue is recognized. The cancer vaccine business is R&D-driven, and its value depends heavily on whether it enters clinical stages.

For that reason, comparing the business with large biopharma growth rates is less informative than comparing margins in logistics and testing against R&D cost burden.

06

Outlook

The company said it expects supply-contract revenue from InnoSEAL Plus DL to be recognized in the second half of 2026, while SCL Healthcare's growth and R&D at its cancer vaccine subsidiary continue.

For 2026 it has pointed to strengthening biologics logistics and expanding medical device sales, with a goal of pairing revenue growth with profitability. The mass spectrometry facility at SCL Healthcare was described as entering full operation from Q2 2026, with improved testing-business results expected.

After the planned merger, the company said it would combine the profit base of its core business with data capabilities and keep investing in precision medicine including cancer vaccines. It presents building a medical data platform and developing cancer vaccines as its core tasks for data-driven precision medicine.

The variable to watch is how quickly R&D spending converts into revenue, since costs from clinical entry were reflected in Q3 2026 operating results, and the point at which the operating loss narrows again is the next checkpoint.

Whether the InnoSEAL Plus DL contract revenue shows up in second-half 2026 results will determine how much the revenue mix changes. Merger terms and timing still need to be set in filings before the change in the consolidated business mix can be gauged.

The 2026 annual business report, the next periodic filing, will fix the fourth-quarter 2026 results and the full-year operating margin.

07

Valuation

PER
—
PBR
2.8×
ROE
-16.5%
EPS
-₩118
BPS
₩677
Dividend per share
₩0

Because the company has recorded net losses attributable to controlling shareholders for the last four quarters, earnings-based multiples cannot be calculated. With value hard to gauge from earnings, net asset value and the pace of revenue growth become the starting points for comparison.

The price-to-book ratio sits above 1x, which means the shares trade at a premium to book net asset value. The debt-to-equity ratio rose to 240.1% at end-2025 from 55.0% in 2024, so the debt structure comes with any reading of that premium.

Dividends are effectively absent, so a comparison on dividend yield does not apply. Because operating losses persisted from 2022 through 2025, the pace of operating margin improvement is the key variable for any valuation comparison.

Against large biopharma companies, the gap in revenue and profit scale is wide, so the same multiple benchmarks cannot be applied directly.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Sustained revenue growth

Revenue rose from KRW 370 million in 2022 to KRW 22 billion in 2025. The company disclosed cumulative consolidated revenue of KRW 23.1 billion for the first three quarters of 2026, up 68% year on year. The Yeongnam and Honam cold chain expansion accounts for roughly half of the first-half revenue increase.

Profitable quarters observed

Operating profit turned positive in Q2 2026 at KRW 406 million. On a standalone basis, first-half 2026 operating results moved from a loss in the prior-year period to a profit. Annual operating losses narrowed every year from 2022 to 2025.

New products and subsidiary profit

Subsidiary SCL Healthcare turned profitable in the first half of 2026, with revenue of KRW 5.05 billion and an operating profit of KRW 57 million. Shipments of InnoSEAL Plus DL and growth in genetic testing are presented as new revenue sources. Supply-contract revenue from the hemostatic product is expected to be reflected in second-half 2026 results.

09

Bear factors

Annual operating and net losses persist

Operating losses continued for four consecutive years from 2022 to 2025, and the net loss attributable to controlling shareholders widened to KRW 3.93 billion in 2025 from KRW 3.73 billion in 2024. The 2025 net loss including non-controlling interests was KRW 4.12 billion.

The operating margin narrowed to -15.4%, but no full-year operating profit appears in the annual results through 2025.

Quarterly results reversing

Q3 2026 returned to an operating loss of KRW 190 million after the Q2 profit. The company has recorded net losses attributable to controlling shareholders for five consecutive quarters from Q3 2025 through Q3 2026. The Q3 2026 loss of KRW 786 million was larger than in the prior quarter. The company said net income included non-cash items such as convertible bond valuation and interest expense.

Balance sheet burden and R&D costs

Total liabilities at end-2025 were KRW 56.4 billion, well above total equity of KRW 23.5 billion, and the debt-to-equity ratio stood at 240.1%. Operating cash flow was negative in every year from 2022 to 2025.

The company attributes the consolidated operating loss in part to higher R&D spending as its cancer vaccine subsidiary moved toward clinical trials.

10

Risk factors

Financial structure

The debt-to-equity ratio rose to 240.1% in 2025, with total liabilities of KRW 56.4 billion. Convertible bond valuation gains and losses and interest expense remain non-cash items that move net income. Funding capacity and the burden of potential conversion are variables that come with this structure.

Concentration and merger variables

Roughly half of the first-half 2026 standalone revenue increase came from the Yeongnam and Honam cold chain business. The planned merger with subsidiary SCL Healthcare could change the consolidated structure and business allocation. Its outcome is difficult to gauge until terms and timing are set.

R&D spending and clinical results

Higher R&D and investment costs from the cancer vaccine subsidiary's move into clinical work contributed to the consolidated operating loss. The company says the core business's profitability has not declined, but clinical results and commercialization timing remain uncertain. How quickly R&D spending converts into revenue will determine the pace of earnings recovery.

11

What to watch next

  1. Mid-February 2027 (estimate)

    Preliminary full-year 2026 results. This timing is estimated from the February 13, 2026 announcement; the point is whether revenue growth continues and whether the operating loss keeps narrowing.

  2. By March 31, 2027

    Filing of the 2026 annual business report on DART. It will contain the finalized full-year operating margin, debt-to-equity ratio, operating cash flow and details on the subsidiary merger.

  3. Mid-May 2027 (estimate)

    Q1 2027 results. This timing is estimated from the May 15, 2026 release for Q1 2026; it will show whether quarterly operating results move back toward profit after the Q2 2026 gain.

12

Overall view

SCL Science's DART-filed results show revenue rising for three consecutive years from 2022 to 2025, reaching KRW 22 billion in 2025, while operating losses persisted for four consecutive years.

The operating margin narrowed from -1,245.4% in 2022 to -15.4% in 2025, yet the net loss attributable to controlling shareholders widened to KRW 3.93 billion in 2025.

Quarterly revenue stayed in a range of roughly KRW 7.6 billion to 7.9 billion in 2026, and cumulative consolidated revenue for the first three quarters of 2026 was KRW 23.1 billion, up 68% year on year. Quarterly operating results returned to a loss of KRW 190 million in Q3 2026 after a profit in Q2.

The debt-to-equity ratio rose to 240.1% at end-2025 from 55.0% in 2024, and operating cash flow was negative every year from 2022 to 2025. Strengths include top-line growth and profitable periods in some units, while weaknesses include persistent annual losses, rising debt and R&D cost burden.

The next checkpoints are the 2026 preliminary annual results, the 2026 annual business report, and the merger terms and timing. This report is for information only and does not present an investment rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. google.com
  2. butler.works
  3. markets.hankyung.com
  4. valueline.co.kr
  5. valueline.co.kr
  6. thevc.kr
  7. markets.hankyung.com
  8. supple.kr
  9. supple.kr
  10. marketin.edaily.co.kr
  11. newspim.com
  12. news.nate.com
  13. daily.hankooki.com
  14. getnews.co.kr
  15. mt.co.kr
  16. newspim.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis